Sabra Health Care REIT Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
SBRA$21.32-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $26,254 | $(9,487) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 42,914 | 52,827 |
| Non-cash rental and related revenues | 591 | (2,398) |
| Non-cash interest income | 7 | (392) |
| Non-cash interest expense | 3,071 | 3,014 |
| Stock-based compensation expense | 2,521 | 2,229 |
| Loss on extinguishment of debt | — | 1,541 |
| Recovery of loan losses | (137) | (208) |
| Net loss on sales of real estate | — | 21,515 |
| Impairment of real estate | 3,137 | 7,064 |
| Loss from unconsolidated joint ventures | 595 | 838 |
| Distributions of earnings from unconsolidated joint ventures | 1,478 | 367 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, prepaid expenses and other assets, net | (6,288) | (2,782) |
| Accounts payable and accrued liabilities | (21,348) | (5,839) |
| Net cash provided by operating activities | 52,795 | 68,289 |
| Cash flows from investing activities: | ||
| Acquisition of real estate | — | (39,630) |
| Origination and fundings of loans receivable | (102) | (1,800) |
| Origination and fundings of preferred equity investments | (1,007) | (6,384) |
| Additions to real estate | (12,935) | (19,540) |
| Repayments of loans receivable | 391 | 6,144 |
| Repayments of preferred equity investments | 617 | 1,433 |
| Investment in unconsolidated joint ventures | (188) | (4,797) |
| Net proceeds from the sales of real estate | — | 152,259 |
| Net proceeds from sales-type lease | — | 25,490 |
| Net cash (used in) provided by investing activities | (13,224) | 113,175 |
| Cash flows from financing activities: | ||
| Net borrowings from (repayments of) revolving credit facility | 52,404 | (118,442) |
| Proceeds from term loans | — | 12,186 |
| Principal payments on secured debt | (503) | (490) |
| Payments of deferred financing costs | (80) | (18,127) |
| Issuance of common stock, net | (2,606) | (1,847) |
| Dividends paid on common stock | (69,444) | (69,351) |
| Net cash used in financing activities | (20,229) | (196,071) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 19,342 | (14,607) |
| Effect of foreign currency translation on cash, cash equivalents and restricted cash | (131) | (641) |
| Cash, cash equivalents and restricted cash, beginning of period | 46,719 | 53,932 |
| Cash, cash equivalents and restricted cash, end of period | $65,930 | $38,684 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $20,495 | $22,318 |
| Supplemental disclosure of non-cash investing activities: | ||
| Decrease in loans receivable and other investments due to acquisition of real estate | $— | $4,644 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.